🔗 Share this article

Given that America undertakes sweeping revisions to its immunization schedules, one figure has emerged somewhat surprisingly: Høeg, a US-based physician and epidemiologist who rose to prominence by expressing skepticism about Covid vaccinations throughout the global health crisis and has zeroed in on potential fatalities following Covid vaccination in her short tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Immunization Schedule

Public health authorities had intended to announce sweeping revisions to the childhood vaccination calendar in December, synchronizing the US with the Danish immunization schedule, sources say – a substantial departure that would put the US out of step with a large portion of the world with little proof for improved outcomes. The planned update has been delayed until the next year.

In place of Vinay Prasad, Høeg is listed to speak at the event. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to lead the office this year.

A Shift at the Regulatory Body

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for discontinuing certain childhood vaccine recommendations in the US to become more like the Danish model, a nation with universal health coverage and a citizenry about the population of Wisconsin’s.

So far statements, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – rather than medication approval.

Doubts Over Background

Dr. Høeg has little discernible experience in pharmaceutical research, oversight or leadership, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in managing a large organization. She is not an expert in drug approvals.”

Former directors of CBER would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that previous people who led the center have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock stated.

“Everybody just pays attention on the new drug program, but the generic program approves numerous off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and more, and all of those must be supervised,” Woodcock said. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Furthermore, a significant management element to the position, which manages over 5,000 personnel. “It’s a huge management job, if you do it right,” the former official added.

Agency Reaction and Disputed Initiatives

When asked about concerns about Dr. Høeg's fitness for the role and whether this selection signifies increased cooperation among agency officials on vaccines, a press secretary said that the “inquiries rely on flawed premises”.

“Her resume aligns with the responsibilities of her position,” the spokesperson said, citing the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a disputed expedited therapy clearance system that allegedly troubled her preceding directors. “How are these medications being selected for this voucher program? Who takes the calls?” Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration looks to be trending towards more relaxed oversight of most medications, except for shots.”

Public Track Record on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if problematic, track record, some experts said. She authored a analysis using non-validated volunteer-provided data to estimate the frequency of heart inflammation after Covid immunization. She advised the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccinations are riskier than they are.

Included in her “policy goals” for the new government included revising guidelines for novel immunizations and ending “unnecessary” immunizations, she stated following the vote on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of excluding teenage boys from receiving Covid vaccines.

“She is an complete true believer who commences with her conclusions and reverse-engineers to fit the science in a highly misleading, fraudulent manner,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined other contrarians, {like|